Soleno Therapeutics, Inc. (SLNO) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $52.82 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: VYKAT XR.
Soleno Therapeutics is a commercial-stage biopharmaceutical company with its first approved product, VYKAT XR (diazoxide choline extended-release), FDA-approved March 2025 to treat hyperphagia in Prader-Willi syndrome patients age 4+. Revenue generation began Q2 2025 with net... Read more
Sell if holding. Analyst target reached at $52.82 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: VYKAT XR. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.
Passes 4/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductVYKAT XR10-K Item 1A: 'we have just begun to generate product revenue and are dependent upon the success of VYKAT XR'
Material Events(8-K, last 90d)
- 2026-02-26Item 5.02MEDIUMCFO James Mackaness announced retirement by end of March 2026; Jennifer Fulk appointed as successor CFO effective March 2, 2026. Mackaness departure not due to disagreement with company.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $52.82 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: VYKAT XR. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $52.58. Score 4.6/10, moderate confidence.
Take-profit target: $51.82 (-1.9% upside). Prior stop was $52.58. Stop-loss: $52.58.
Concentration risk — Product: VYKAT XR; Analyst target reached - limited upside remaining; Earnings in 6 days (event risk).
Soleno Therapeutics, Inc. trades at a P/E of 135.3 (forward -23.3). TrendMatrix value score: 1.9/10. Verdict: Sell.
19 analysts cover SLNO with a consensus score of 4.3/5. Average price target: $53.
What does Soleno Therapeutics, Inc. do?Soleno Therapeutics is a commercial-stage biopharmaceutical company with its first approved product, VYKAT XR...
Soleno Therapeutics is a commercial-stage biopharmaceutical company with its first approved product, VYKAT XR (diazoxide choline extended-release), FDA-approved March 2025 to treat hyperphagia in Prader-Willi syndrome patients age 4+. Revenue generation began Q2 2025 with net income of $20.9M for full year 2025.